11 Eylül 2026, Cuma · 16:35 Piyasalar Açık
borsapanel.com Borsanın nabzı, tek panelde.
Abone Ol

Çekirdek Bilim Direktörü 7.000 Hisse Satın Aldı

Core Scientific Director Purchases 7,000 Shares

Jack Delaney, The Motley Fool

Wed, September 9, 2026 at 12:50 AM GMT+3 4 min read

Eric Stanton Weiss, a Director at Core Scientific (NASDAQ:CORZ), purchased 7,000 shares of common stock on Aug. 18, 2026, according to a recent SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average purchase price ($19.19); post-transaction value based on Aug. 18, 2026, market close ($18.85).

Key questions

  • What was the execution context for this purchase?
    The shares were acquired in multiple transactions at prices ranging from $18.78 to $19.59, resulting in a weighted-average cost of $19.19 per share.

  • How does this purchase affect the director's total stake?
    Weiss now directly holds 259,262 shares of common stock, representing an 0.08% ownership interest in the company.

  • What are the core business operations of the company?
    Core Scientific is a North American enterprise primarily engaged in digital asset mining and providing colocation services for distributed ledger technology, operating specialized data centers to process blockchain transactions.

  • How has the stock performed leading up to this transaction?
    The company's shares were priced at $18.72 as of the Aug. 19, 2026, market close, following a period where the stock delivered a 30% return over the 12 months ending on the transaction date.

Company Overview

Company Snapshot

  • Core Scientific operates digital asset mining facilities and provides colocation services for distributed ledger technology infrastructure, generating revenue through proprietary cryptocurrency mining operations and hosting services for third-party blockchain network participants.

  • The company generates revenue through two primary channels: direct digital asset mining conducted within its owned and operated data centers, and colocation services that leverage its specialized computing hardware and infrastructure to support external clients' blockchain operations.

  • Core Scientific serves enterprise clients and digital asset participants who require high-performance computing infrastructure, targeting organizations seeking reliable, scalable hosting solutions for blockchain network operations and cryptocurrency mining.

Core Scientific operates a substantial North American infrastructure platform with 325 employees and $6 billion in market capitalization, positioning itself as a significant player in the digital asset mining and blockchain infrastructure sectors. The company's competitive advantage derives from its owned-and-operated data centers, equipped with specialized computing hardware optimized for blockchain transaction processing and digital asset mining. With TTM revenue of $440.3 million, Core Scientific has established a material revenue base while navigating the capital-intensive and volatile digital asset market through diversified revenue streams combining proprietary mining operations with third-party colocation services.

What this transaction means for investors

The Core Scientific stock price has performed well over the last year, climbing 34.4%. In comparison, the S&P 500 is up 18.1% over the same period. With a strong performance like that, it may be common to see some executives sell shares. But an insider buying into a rising stock price is a bullish signal for shareholders, as it indicates that Weiss expects shares to keep climbing. His purchase of 7,000 shares adds to his substantial holdings that now total nearly 260,000.

In addition to Weiss's purchase, another bullish signal for Core Scientific's stock price is how analysts view the company. Out of 18 who cover the stock, 94% rate it a buy, while 6% rate it a hold, according to CNN. From that group, the median one-year price target is $36, representing a gain of 92.2% from today's price ($18.73). The highest price target of $55 is even more bullish, representing a 193.6% gain. And even the lowest price target, $28, would still represent a gain of nearly 50%. With a rising stock price, insider buying, and bullish analyst outlooks, there are a lot of positive signals about where the Core Scientific stock price could head next.

Should you buy stock in Core Scientific right now?

Before you buy stock in Core Scientific, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Core Scientific wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,413,876!*

That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of September 8, 2026.

Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Core Scientific Director Purchases 7,000 Shares was originally published by The Motley Fool

Kaynak: Yahoo Finance
İlgili Haberler
Global Bir akşam yemeğine gittim, meze ve şarap getirdim ve ev sahibi benden 60 $ istedi. Onunla bağlarımı kesmeli miyim? MarketWatch Top · 7 dk önce Global Alman sendikası, Volkswagen'in 2024 iş sözleşmesi taahhüdünü talep ediyor Investing.com · 10 dk önce Global BlackRock özel kredi fonu itfası üçüncü çeyrekte kolaylık talep ediyor Investing.com · 11 dk önce Global Ocean Capital Acquisition CFO'su istifa etti, CEO geçici finans rolünü üstlendi Investing.com · 12 dk önce Global Cantor konferansında Helus Pharma: Faz III okuması odakta Investing.com · 14 dk önce

Yorumlar (0)

Giriş yaparak yorum yazabilirsin.

İlk yorumu sen yaz.